Biotechnology company Thalia Therapeutics has acquired Sanmirna Therapeutics and its clinical-stage cancer RNA therapy. The acquisition catapults Thalia to a clinical-stage RNA therapeutics company, leveraging Sanmirna’s anti-microRNA-126 for the treatment of acute myeloid leukaemia. The deal is believed to be worth £16.675 million ($21.984 million), encompassing an initial consideration of £3.675 million ($4.845 million) and £13 million ($17 […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!